概览
Short Course
Conference: January 24-26
Safety monitoring of medicines is imperative for ensuring health and wellbeing of patients worldwide. For pharmacovigilance professionals, the complexity of safety and pharmacovigilance efforts is heightened by the rapid development of multiple vaccines and treatments, the emergent nature of knowledge about the etiology of the corona virus disease, and pervasive misinformation about prevention and treatment practices. The current challenges are ongoing and will have lasting impact on safety, pharmacovigilance, and other related PV activities, such as risk management.
DIA's Global Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies, this conference provides the background, context, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field.
For this year’s program, stakeholders from medicines research, global regulation, and healthcare will join to analyze the challenges for safety and pharmacovigilance efforts in this uncertain environment and examine effective strategies for addressing gaps and needs. New approaches and collaborations that build on the foundation of sound pharmacovigilance principles to optimize safety and pharmacovigilance practice and ensure safe medicines for patients will be explored, in a global and regional context.
Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. If the capacity limit is reached, we will only be able to offer the virtual option. Don’t miss out on your chance to meet live again with your friends and colleagues!
Featured
Want to learn more about DIA Global Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!
项目委员会
-
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States -
Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
IQVIA, United States -
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol Myers Squibb, United States -
James Buchanan, PharmD President
Covilance LLC, United States -
Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
FDA, United States -
E. Stewart Geary, MD MD, Global Safety Officer
Eisai Co., Ltd., Japan -
Jeremy Jokinen, PhD, MS Vice President and Head Global Patient Safety
Argenx, United States -
Jamie Ridley Klucken, PharmD, MBA, RPh Safety Evaluator, Division of Pharmacovigilance, OSE, CDER
FDA, United States -
Linda J. Scarazzini, MD, RPh Vice President, Pharmacovigilance and Patient Safety
AbbVie, United States -
Sarah Vaughan Head of Vigilance Operations
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Annette Stemhagen, DrPH, PhD, FISPE Chief Science Officer
UBC, United States -
Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States